200 related articles for article (PubMed ID: 31589995)
1. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: A large single-center cohort study.
Zhang Y; Xiong X; Fu Z; Dai H; Yao F; Liu D; Deng S; Hu C
Eur J Radiol; 2019 Nov; 120():108695. PubMed ID: 31589995
[TBL] [Abstract][Full Text] [Related]
2. Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study.
Wu C; Huang J; Xu WB; Guan YJ; Ling HW; Mi JQ; Yan H
Acad Radiol; 2018 Jul; 25(7):904-914. PubMed ID: 29373210
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma.
Lacognata C; Crimì F; Guolo A; Varin C; De March E; Vio S; Ponzoni A; Barilà G; Lico A; Branca A; De Biasi E; Gherlinzoni F; Scapin V; Bissoli E; Berno T; Zambello R
Clin Radiol; 2017 Oct; 72(10):850-857. PubMed ID: 28587715
[TBL] [Abstract][Full Text] [Related]
4. Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
Latifoltojar A; Hall-Craggs M; Bainbridge A; Rabin N; Popat R; Rismani A; D'Sa S; Dikaios N; Sokolska M; Antonelli M; Ourselin S; Yong K; Taylor SA; Halligan S; Punwani S
Eur Radiol; 2017 Dec; 27(12):5325-5336. PubMed ID: 28656463
[TBL] [Abstract][Full Text] [Related]
5. Apparent diffusion coefficient maps integrated in whole-body MRI examination for the evaluation of tumor response to chemotherapy in patients with multiple myeloma.
Bonaffini PA; Ippolito D; Casiraghi A; Besostri V; Franzesi CT; Sironi S
Acad Radiol; 2015 Sep; 22(9):1163-71. PubMed ID: 26182979
[TBL] [Abstract][Full Text] [Related]
6. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.
Horger M; Weisel K; Horger W; Mroue A; Fenchel M; Lichy M
AJR Am J Roentgenol; 2011 Jun; 196(6):W790-5. PubMed ID: 21606271
[TBL] [Abstract][Full Text] [Related]
7. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Giles SL; Messiou C; Collins DJ; Morgan VA; Simpkin CJ; West S; Davies FE; Morgan GJ; deSouza NM
Radiology; 2014 Jun; 271(3):785-94. PubMed ID: 24475858
[TBL] [Abstract][Full Text] [Related]
8. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.
Park HY; Kim KW; Yoon MA; Lee MH; Chae EJ; Lee JH; Chung HW; Yoon DH
Cancer Imaging; 2020 Jan; 20(1):14. PubMed ID: 32000858
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Early Treatment Response in Multiple Myeloma Using MY-RADS Total Burden Score, ADC, and Fat Fraction From Whole-Body MRI: Impact of Anemia on Predictive Performance.
Dong H; Huang W; Ji X; Huang L; Zou D; Hao M; Deng S; Shen Z; Lu X; Wang J; Song Z; Zhang X; Xue H; Xia S
AJR Am J Roentgenol; 2022 Feb; 218(2):310-319. PubMed ID: 34523949
[No Abstract] [Full Text] [Related]
10. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
[TBL] [Abstract][Full Text] [Related]
11. Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI.
De Paepe KN; De Keyzer F; Wolter P; Bechter O; Dierickx D; Janssens A; Verhoef G; Oyen R; Vandecaveye V
J Magn Reson Imaging; 2018 Oct; 48(4):897-906. PubMed ID: 29656584
[TBL] [Abstract][Full Text] [Related]
12. Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
Latifoltojar A; Hall-Craggs M; Rabin N; Popat R; Bainbridge A; Dikaios N; Sokolska M; Rismani A; D'Sa S; Punwani S; Yong K
Br J Haematol; 2017 Jan; 176(2):222-233. PubMed ID: 27766627
[TBL] [Abstract][Full Text] [Related]
13. Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI.
Takasu M; Kondo S; Akiyama Y; Takahashi Y; Maeda S; Baba Y; Kawase T; Ichinohe T; Awai K
PLoS One; 2020; 15(2):e0229607. PubMed ID: 32106239
[TBL] [Abstract][Full Text] [Related]
14. Repeatability and test-retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI).
ElGendy K; Barwick TD; Auner HW; Chaidos A; Wallitt K; Sergot A; Rockall A
Br J Radiol; 2022 Sep; 95(1138):20220418. PubMed ID: 35867890
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal monitoring of apparent diffusion coefficient (ADC) in myeloma patients with lower M-gradient levels undergoing systemic treatment and whole-body MRI monitoring.
Perl RM; Gronbach F; Fritz J; Horger MS; Hepp T
Eur J Radiol; 2020 Nov; 132():109306. PubMed ID: 33038578
[TBL] [Abstract][Full Text] [Related]
16. Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging.
Bourillon C; Rahmouni A; Lin C; Belhadj K; Beaussart P; Vignaud A; Zerbib P; Pigneur F; Cuenod CA; Bessalem H; Cavet M; Boutekadjirt A; Haioun C; Luciani A
Radiology; 2015 Dec; 277(3):773-83. PubMed ID: 26131910
[TBL] [Abstract][Full Text] [Related]
17. Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma.
Wang J; Zhang B; Zhang R; Zhang L; Jiang W; Jiang Y
Medicine (Baltimore); 2021 Sep; 100(35):e27131. PubMed ID: 34477159
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Whole-Body DWI and
Chen J; Li C; Tian Y; Xiao Q; Deng M; Hu H; Wen B; He Y
AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
[No Abstract] [Full Text] [Related]
19. Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.
Sasaki M; Tozaki M; Kubota K; Murakami W; Yotsumoto D; Sagara Y; Ohi Y; Oosako S; Sagara Y
Jpn J Radiol; 2018 Feb; 36(2):122-133. PubMed ID: 29159779
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Poor Responders to Neoadjuvant Chemotherapy in Patients with Osteosarcoma: Additive Value of Diffusion-Weighted MRI including Volumetric Analysis to Standard MRI at 3T.
Lee SK; Jee WH; Jung CK; Im SA; Chung NG; Chung YG
PLoS One; 2020; 15(3):e0229983. PubMed ID: 32155203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
